Interindividual variability in inhibition and induction of cytochrome P450 enzymes

被引:194
|
作者
Lin, JH [1 ]
Lu, AYH
机构
[1] Merck Res Labs, Dept Drug Metab, West Point, PA 19486 USA
[2] Rutgers State Univ, Coll Pharm, Canc Res Lab, Piscataway, NJ 08854 USA
关键词
quantitative prediction of drug interactions; intestinal first-pass metabolism; genetic polymorphism; drug interactions;
D O I
10.1146/annurev.pharmtox.41.1.535
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug interactions have always been a major concern in medicine for clinicians and patients. Inhibition and induction of cytochrome P450 (CYP) enzymes are probably the most common causes for documented drug interactions. Today, many pharmaceutical companies are predicting potential interactions of new drug candidates. Can in vivo drug interactions be predicted accurately from in vitro metabolic studies? Should the prediction be qualitative or quantitative? Although some scientists believe that quantitative prediction of drug interactions is possible, others are less optimistic and believe that quantitative prediction would be very difficult. There are many factors that contribute to our inability to quantitatively predict drug interactions. One of the major complicating factors is the large interindividual variability in response to enzyme inhibition and induction. This review examines the sources that are responsible for the interindividual variability in inhibition and induction of cytochrome P450 enzymes.
引用
收藏
页码:535 / 567
页数:33
相关论文
共 50 条
  • [21] Induction of rat hepatic cytochrome P450 enzymes by myristicin
    Jeong, HG
    Yun, CH
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 217 (03) : 966 - 971
  • [22] Cytochrome P450 enzymes in chickens: characteristics and induction by xenobiotics
    Gupta, RP
    Abou-Donia, MB
    COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-PHARMACOLOGY TOXICOLOGY & ENDOCRINOLOGY, 1998, 121 (1-3): : 73 - 83
  • [23] Reversible and Irreversible Inhibition of Cytochrome P450 Enzymes by Methylophiopogonanone A
    Tu, Dong-Zhu
    Mao, Xu
    Zhang, Feng
    He, Rong-Jing
    Wu, Jing-Jing
    Wu, Yue
    Zhao, Xiao-Hua
    Zheng, Jiang
    Ge, Guang-Bo
    DRUG METABOLISM AND DISPOSITION, 2021, 49 (06) : 459 - 469
  • [24] The Role of Drug Metabolites in the Inhibition of Cytochrome P450 Enzymes
    Mikov, Momir
    Danic, Maja
    Pavlovic, Nebojsa
    Stanimirov, Bojan
    Golocorbin-Kon, Svetlana
    Stankov, Karmen
    Al-Salami, Hani
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2017, 42 (06) : 881 - 890
  • [25] The Role of Drug Metabolites in the Inhibition of Cytochrome P450 Enzymes
    Momir Mikov
    Maja Đanić
    Nebojša Pavlović
    Bojan Stanimirov
    Svetlana Goločorbin-Kon
    Karmen Stankov
    Hani Al-Salami
    European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42 : 881 - 890
  • [26] Inhibition of curcumenol to human liver cytochrome P450 enzymes
    Song, Dong-Xue
    Fang, Zhong-Ze
    Zhang, Yan-Yan
    Yang, Ling
    DRUG METABOLISM REVIEWS, 2009, 41 : 74 - 74
  • [27] Cytochrome P450 enzymes in the heart
    Seubert, J
    Yang, BC
    Bradbury, A
    Graves, J
    Miller, L
    Murphy, E
    Zeldin, DC
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2004, 36 (05) : 772 - 772
  • [28] Engineering cytochrome P450 enzymes
    Gillam, Elizabeth M. J.
    CHEMICAL RESEARCH IN TOXICOLOGY, 2008, 21 (01) : 220 - 231
  • [29] Cytochrome P450 enzymes in the vasculature
    Fleming, I
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2004, 36 (05) : 728 - 729
  • [30] Cytochrome P450 Enzymes and the Heart
    Chaudhary, Ketul R.
    Batchu, Nagarjun
    Seubert, John M.
    IUBMB LIFE, 2009, 61 (10) : 954 - 960